More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Analysts expect modest revenue growth but pressure on profitability in the March quarter
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Subscribe To Our Newsletter & Stay Updated
